D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Accounts Payable
ÂĄ108.9m
CAGR 3-Years
19%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accounts Payable
ÂĄ3.7B
CAGR 3-Years
20%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accounts Payable
ÂĄ299.9m
CAGR 3-Years
39%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Accounts Payable
ÂĄ1.1B
CAGR 3-Years
25%
CAGR 5-Years
85%
CAGR 10-Years
39%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accounts Payable
ÂĄ16.3B
CAGR 3-Years
41%
CAGR 5-Years
47%
CAGR 10-Years
91%
Imeik Technology Development Co Ltd
SZSE:300896
Accounts Payable
ÂĄ44.7m
CAGR 3-Years
113%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.4B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
30.31 CNY
Overvaluation 33%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Accounts Payable?
Accounts Payable
108.9m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Accounts Payable amounts to 108.9m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
14%

Over the last year, the Accounts Payable growth was -29%. The average annual Accounts Payable growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 19% over the past three years , 14% over the past five years .

Back to Top